This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): J695, anti–Interleukin-12, briakinumab, Ozespa (EU)
Description: ABT-874 is a fully human anti-IL-12/23 monoclonal antibody designed to target and neutralize IL-12, a protein that regulates inflammatory response and is expressed in MS lesions.
Deal Structure: CAT, in conjunction with Abbott, has isolated and optimised human monoclonal antibodies against the first two nominated targets, TNF alpha and Interleukin-12, and these antibodies are now in clinical trials (HUMIRA and ABT-874 respectively). The development of ABT-874 involved the partnership of Abbott and the Genetics Institute (a research unit of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products) together with CAT.
In June 2006, CAT became a subsidiary of AstraZeneca.
Partners: AstraZeneca PLC
Additional information available to subscribers only: